Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2030-06-30
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, multi-arm, non-randomized, open-label clinical trial to
evaluate the efficacy and safety of neoadjuvant intensive endocrine therapy for high-risk or
locally progressive prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School